Testing effectiveness (Phase 2)Not Yet RecruitingNCT06780839
What this trial is testing
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Who this might be right for
NSCLC, Stage I, II, IIIA, IIIB
Peking University Cancer Hospital & Institute 70